Bionomics Ltd is a global, clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company's reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.
Quote | Bionomic Ltd Par Ord (OTCMKTS:BNOEF)
Last: | $0.006 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $0.006 |
High: | $0 |
Low: | $0 |
Volume: | 22,939 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Bionomic Ltd Par Ord (OTCMKTS:BNOEF)
The following slide deck was published by Bionomics Limited in conjunction with this event. For further details see: Bionomics (BNOX) Investor Presentation - Slideshow
Bionomics Limited Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs in the United States PR Newswire EASTWOOD, Australia , Jan. 5, 2022 /PRNewswire/ -- Bionomics Limited ( Bionomics or Company ), a clinical-stage biopharmaceutica...
Message Board Posts | Bionomic Ltd Par Ord (OTCMKTS:BNOEF)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $BNOEF News Article - Bionomics Limited Announces Pricing of Initial Public Offering in | whytestocks | investorshangout | 12/16/2021 3:20:48 PM |
$BNOEF: Also focused on Psychedlics | makinezmoney | investorshub | 11/23/2021 11:50:28 AM |
$BNOEF: Files Registration Statement or IPO in the US | makinezmoney | investorshub | 11/23/2021 11:46:50 AM |
whytestocks: $BNOEF News Article - Bionomics BNC210 Expansion into Social Anxiety Disorder | whytestocks | investorshangout | 05/10/2021 8:25:49 PM |
whytestocks: $BNOEF News Article - Positive BNC210 7-Day Dosing Pharmacokinetic Study Exceeds Blood | whytestocks | investorshangout | 02/22/2021 1:15:47 PM |
News, Short Squeeze, Breakout and More Instantly...
Bionomic Ltd Par Ord Company Name:
BNOEF Stock Symbol:
OTCMKTS Market:
Bionomic Ltd Par Ord Website:
Bionomics Limited Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs in the United States PR Newswire EASTWOOD, Australia , Jan. 5, 2022 /PRNewswire/ -- Bionomics Limited ( Bionomics or Company ), a clinical-stage biopharmaceutica...
Bionomics Limited Announces Pricing of Initial Public Offering in the United States PR Newswire ADELAIDE, Australia , Dec. 16, 2021 /PRNewswire/ -- Bionomics Limited ( Bionomics or Company ), a clinical-stage biopharmaceutical company, today announced the...
U.S. FDA Grants Bionomics Fast Track Designation to BNC210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders PR Newswire ADELAIDE, Australia , Dec. 1, 2021 /PRNewswire/ -- Bionomics Limited (ASX:BNO, OTCQB:BNOEF) ( Bion...